thumbnail image
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
    broken image
    broken image

    seek and you will find

    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
    • …  
      • Home
      • Technology
      • Products 
        • Products Overview
        • SeekInCare
        • SeekInCure
        • SeekInClarity
        • OncoSeek
        • LeukoPrint
      • Publication 
        • Research
        • Others
      • Newsroom
      • Product & Service Inquiry
      broken image
      • LeukoPrintTM

        The first-in-class leukemia sWGS CNA test

        broken image

        By evaluating the copy number aberration (CNA) in bone marrow cells and/or circulating cell free DNA (cfDNA) via shallow whole genome sequencing (sWGS), in conjunction with conventional cytogenetics, LeukoPrintTM makes leukemia diagnosis, molecular subtyping, prognostic stratification and treatment responds monitoring more precise and comprehensive.

      • broken image

        Without culturing cells in vitro

        broken image

        High sensitivity and low failure rate

        broken image

        Automatic readout system

      • An example of CNA profiling of LeukoPrintTM reveals abnormal karyotype at molecular level

        broken image
        LeukoPrintTM Karyotyping

        Specifications

        ◉ Indicated subjects:Patients with suspected or confirmed leukemia (MDS/AML/ALL/CLL/MM)

        ◉ Sample requirement:1-2ml bone marrow or 10ml blood

        ◉ Result readout:copy number aberration(CNA)

        ◉ Turnaround time (TAT):7 working days

      •  

        How it works

        broken image

        Pre-test inquiry

         

        broken image

        Informed consent 

        broken image

        Blood-draw

        broken image

        Testing

        broken image

        Analyzing + Interpretation

         

        broken image

        Reporting

         

      Navigation

      Technology   

      SeekInCare

      SeeInCure

      SeekInClarity

      OncoSeek

      Research

      Contact Us

      10320 Camino Santa Fe, Suite G

      San Diego, CA 92121

      United States

      info@seekincancer.com

      © 2024 SeekIn Inc.

      All Rights Reserved.

      Cookie Use
      We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
      Learn More